- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Silo Pharma reports stability data for intranasal drug SPC-15 | 1 | Investing.com | ||
| Di | Silo Pharma, Inc.: Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial | 2 | GlobeNewswire (USA) | ||
| Do | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Silo Pharma regains Nasdaq bid price compliance | 1 | Seeking Alpha | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Silo Pharma, Inc.: Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | 197 | GlobeNewswire (Europe) | SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
| 01.06. | Silo Pharma kündigt Aktienzusammenlegung im Verhältnis 1:15 an | - | Investing.com Deutsch | ||
| 01.06. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Silo Pharma, Inc.: Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury | 442 | GlobeNewswire (Europe) | New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved... ► Artikel lesen | |
| 29.04. | Silo Pharma, Inc.: Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD | 176 | GlobeNewswire (Europe) | Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma... ► Artikel lesen | |
| 22.04. | Silo Pharma launches AI subsidiary, advances PTSD drug program | 3 | Investing.com | ||
| 22.04. | Silo Pharma, Inc.: Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents | 1.070 | GlobeNewswire (Europe) | Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| 20.04. | Silo Pharma highlights PTSD treatment program amid policy shift | 2 | Investing.com | ||
| 20.04. | Silo Pharma highlights PTSD drug program amid policy shift | 1 | Investing.com | ||
| 20.04. | Silo Pharma rückt PTSD-Programm nach politischem Kurswechsel in den Fokus | 1 | Investing.com Deutsch | ||
| 20.04. | Silo Pharma, Inc.: Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | 637 | GlobeNewswire (Europe) | SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage... ► Artikel lesen | |
| 07.04. | Silo Pharma-Aktie schießt nach europäischer Patent-Zusage in die Höhe | 1 | Investing.com Deutsch | ||
| 07.04. | Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket | 2 | Benzinga.com | ||
| 07.04. | Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline-UnitedHealth, Silo Pharma, Phillips 66 In Focus | 5 | Benzinga.com | ||
| 07.04. | Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know | 1 | Benzinga.com | ||
| 06.04. | Silo Pharma receives European patent approval for stress prevention therapy | 1 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,90 | -1,00 % | Söllner: Nvidia, Intel; krasses Roboter-Ziel. Bitcoin böse, SpaceX, Palantir gut?! BioNTech, OHB | Heute stand der Hot Stock Report ganz im Zeichen der großen Frage, welche Aktien sich eher auf der "guten" und welche auf der "bösen" Seite der Börse einordnen lassen. Im Mittelpunkt stand dabei vor... ► Artikel lesen | |
| VALNEVA | 2,325 | -0,09 % | Was Insider bei Valneva heute bereits wissen: 0,0% Plus und das könnte erst der Anfang sein - Was erfahrene Trader jetzt tun | ||
| AMGEN | 310,65 | +1,92 % | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| NOVAVAX | 8,190 | +3,67 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| BIOGEN | 175,64 | +1,37 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| ILLUMINA | 151,20 | +4,35 % | IQM Quantum Computers: IQM ernennt Craig Ciesla, ehemaligen Illumina VP, zum CTO und Inés de Vega wird Chief Scientist | Ciesla ist eine erfahrene Tech-Führungskraft mit mehr als 25 Jahren Erfahrung mit der Entwicklung von Produkten von Startups bis Fortune 500-Unternehmen.
De Vega hat mehr als 20 Jahre Erfahrung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,900 | +0,98 % | Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year | ||
| VIVOSIM LABS | 1,120 | -0,88 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,800 | +3,92 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults | Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019
Potential to further expand Viking's treatment options for weight loss
... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 14,000 | +4,48 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 42,945 | +0,56 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| EDITAS MEDICINE | 2,440 | +0,83 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| VIVORYON THERAPEUTICS | 1,060 | +2,42 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,468 | +3,55 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen |
Das Unternehmen SILO PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,980 Euro und damit -4,17 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILO PHARMA INC finden Sie auf Wallstreet Online.